Efficacy of sentinel lymph-node biopsy after neoadjuvant chemotherapy in clinically axilla node-negative patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer International Country of Publication: Japan NLM ID: 9204360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-2813 (Electronic) Linking ISSN: 09411291 NLM ISO Abbreviation: Surg Today Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tokyo : Springer International, c1992-
    • Subject Terms:
      Sentinel Lymph Node Biopsy*/methods ; Neoadjuvant Therapy* ; Breast Neoplasms*/pathology ; Breast Neoplasms*/drug therapy ; Breast Neoplasms*/surgery ; Axilla* ; Lymph Node Excision*; Humans ; Female ; Middle Aged ; Aged ; Adult ; Positron Emission Tomography Computed Tomography ; Magnetic Resonance Imaging ; Lymphatic Metastasis ; Indocyanine Green/administration & dosage
    • Abstract:
      Purpose: Breast cancer is the most common cancer in women. Developments in breast cancer treatment have extended the life expectancy of these patients, raising the issue of morbidity of breast cancer surgery, the major cause of which is axillary dissection. The aim of the present study was to establish the safety of sentinel node biopsy (SLNB) in patients with a clinically node-negative axilla after neoadjuvant chemotherapy (NACT).
      Methods: We recorded demographic data, as well as the findings of physical examination, imaging, and pathology before and after NACT. SLNB with indocyanine green + isosulfan blue and axillary dissection were performed and the surgical and pathology findings were recorded.
      Results: A sentinel lymph node was detected in 80 of 90 patients who underwent surgery. When ≥ three sentinel lymph nodes were removed as negative in the patient group with cN0 after treatment, we evaluated the axilla as being negative with an accuracy of 100%.
      Conclusions: Axillary lymph-node dissection may not be necessary for patients with cNO confirmed by physical and radiological examination using positron emission tomography (PET) computed tomography (CT), and breast magnetic resonance imaging (MRI) after NACT, if ≥ three negative SLNB are removed. Further studies are needed to confirm our findings.
      (© 2024. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.)
    • References:
      Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. (PMID: 10.3322/caac.2149230207593)
      Yang Y, Liu G, Qin L, Ye L, Zhu F, Ying Y. Overexpression of UHRF1 and its potential role in the development of invasive ductal breast cancer validated by integrative bioinformatics and immunohistochemistry analyses. Transl Cancer Res. 2019;8(4):1086–96. (PMID: 10.21037/tcr.2019.06.19351168518797458)
      De Meric de Bellefon M, Lemanski C, Ducteil A, Fenoglietto P, Azria D, Bourgier C. Management of the axilla in the era of breast cancer heterogeneity. Front Oncol. 2018;8:84. (PMID: 10.3389/fonc.2018.00084296708535893721)
      Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. (PMID: 10.1016/S1470-2045(10)70207-2208637593041644)
      Peek MCL, Saeki K, Ohashi K, Chikaki S, Baker R, Nakagawa T, et al. Optimization of SPIO injection for sentinel lymph node dissection in a rat model. Cancers (Basel). 2021;13(19):5031. (PMID: 10.3390/cancers1319503134638516)
      Citgez B, Yigit B, Yetkin SG. Management of the axilla and the breast after neoadjuvant chemotherapy in patients with breast cancer: a systematic review. Med Bull SisliEtfal Hospital. 2021;55(2):156.
      Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61. (PMID: 10.1001/jama.2013.278932241011694075763)
      Cao S, Liu X, Cui J, Liu X, Zhong J, Yang Z, et al. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients. Breast. 2021;59:256–69. (PMID: 10.1016/j.breast.2021.07.015343253838334738)
      Guo J, Yang H, Wang S, Cao Y, Liu M, Xie F, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol. 2017;15(1):196. (PMID: 10.1186/s12957-017-1264-7290966435667473)
      Chirappapha P, Chatmongkonwat T, Lertsithichai P, Pipatsakulroj W, Sritara C, Sukarayothin T. Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine green: prospective cohort study. Ann Med Surg (Lond). 2020;59:156–60. (PMID: 10.1016/j.amsu.2020.09.030330723087548931)
      Tsuyuki S, Yamaguchi A, Kawata Y, Kawaguchi K. Assessing the effects of neoadjuvant chemotherapy on lymphatic pathways to sentinel lymph nodes in cases of breast cancer: usefulness of the indocyanine green-fluorescence method. Breast. 2015;24(3):298–301. (PMID: 10.1016/j.breast.2015.02.03425802085)
      Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-nodebiopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentrecohortstudy. LancetOncol. 2013;14(7):609–18.
      Sancar BAYAR, Seher DEMİRER Lokal İleri Meme Kanserinde Cerrahi Tedavi TürkiyeCumhuriyetiSağlıkBakanlığıSağlıkHizmetleriGenelMüdürlüğü, Meme KanseriKorunma, Tarama, Tanı, TedaviveİzlemKlinikRehberi (Versiyon 1.0, Ankara, 2020p. 68).
      Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J ClinOncol. 2015;33(3):258–64. (PMID: 10.1200/JCO.2014.55.7827)
      Kang SH, Kang JH, Choi EA, Lee ES. Sentinel lymph node biopsy after neoadjuvant chemotherapy. Breast Cancer. 2004;11(3):233–41 (discussion 264-6). (PMID: 10.1007/BF0298454315550841)
      Ozmen V, Unal ES, Muslumanoglu ME, Igci A, Canbay E, Ozcinar B, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J SurgOncol. 2010;36(1):23–9. (PMID: 10.1016/j.ejso.2009.10.015)
      Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804–12. (PMID: 10.1016/j.ejso.2020.10.01433092968)
    • Contributed Indexing:
      Keywords: Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy
    • Accession Number:
      IX6J1063HV (Indocyanine Green)
    • Publication Date:
      Date Created: 20240416 Date Completed: 20240822 Latest Revision: 20240822
    • Publication Date:
      20240822
    • Accession Number:
      10.1007/s00595-024-02837-7
    • Accession Number:
      38627281